机构:[1]Department of Molecular and Cellular Oncology, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, University of Texas, Houston, Texas.[2]Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.[3]Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Guangxi, China.[4]Sun Yat-sen University Cancer Center Key Laboratory of Oncology, South China Collaborative Innovative Center for Cancer Medicine, Guangzhou, China.中山大学肿瘤防治中心
第一作者机构:[1]Department of Molecular and Cellular Oncology, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, University of Texas, Houston, Texas.[*1]The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
通讯作者:
通讯机构:[1]Department of Molecular and Cellular Oncology, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, University of Texas, Houston, Texas.[*1]The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
推荐引用方式(GB/T 7714):
Paul J. Chiao,Jianhua Ling,Jie Fu,et al.Inhibition of Pancreatic Cancer by RhIL1RA-Response[J].CLINICAL CANCER RESEARCH.2017,23(12):3224-3224.doi:10.1158/1078-0432.CCR-17-0083.
APA:
Paul J. Chiao,Jianhua Ling,Jie Fu,Yu Lu&Yi-Chen Sun.(2017).Inhibition of Pancreatic Cancer by RhIL1RA-Response.CLINICAL CANCER RESEARCH,23,(12)
MLA:
Paul J. Chiao,et al."Inhibition of Pancreatic Cancer by RhIL1RA-Response".CLINICAL CANCER RESEARCH 23..12(2017):3224-3224